Clinical trials: Lines Skin
Adenocarcinoma of the Pancreas, Advanced Solid Tumors
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival.
- Conditions
- Adenocarcinoma of the Pancreas, Advanced Solid Tumors, Cancer, Cancer of Pancreas
- Trial name
- GAMMA (NCT01231347)
- Testing
- AMG 479, gemcitabine
- Where
- 152 sites in United States, Australia and 30 more
- Volunteers
- 800 people
- Sponsor
- NantCell, Inc.
Breast Neoplasms
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced…
- Trial name
- NCT02297438
- Testing
- Palbociclib, Letrozole
- Where
- 54 sites in China, Hong Kong and 3 more
- Volunteers
- 340 people
- Sponsor
- Pfizer
Melanoma
Phase II, 2nd Line Melanoma - RAND Monotherapy
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137…
- Trial name
- NCT00612664
- Testing
- Anti-CD137 (4-1BB) (BMS-663513)
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 158 people
- Sponsor
- Bristol-Myers Squibb
Triple Negative Breast Cancer (TNBC)
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who…
- Trial name
- NCT05555706
- Testing
- B013+Nab-Paclitaxel
- Where
- 13 sites in China
- Volunteers
- 62 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Triple Negative Breast Cancer
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
The purpose of this study is to evaluate the efficacy of SKB264 in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed second-line or above prior standard of care
- Trial name
- NCT05347134
- Testing
- SKB264
- Where
- 2 sites in China
- Volunteers
- 254 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Advanced or Metastatic Breast Cancer
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer.
- Trial name
- NCT06105632
- Testing
- PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus
- Where
- 48 sites in United States, Argentina and 12 more
- Volunteers
- 333 people
- Sponsor
- Pfizer
Breast Cancer
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
The purpose of this study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel as first-line treatment in subjects with human epidermal growth factor 2 non-overexpressing…
- Trial name
- NCT01038804
- Testing
- YM155, Docetaxel
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 101 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis
The mail goal of this study is to establish superiority in efficacy of Acellbia® applied in a dose of 600 mg (Day 1 and Day 15) in combination with methotrexate in patients with active RA seropositive previously untreated with…
- Trial name
- ALTERRA (NCT02744196)
- Testing
- Acellbia, Methotrexate
- Volunteers
- 159 people
- Sponsor
- Biocad
Genetic Disorder, Noonan Syndrome
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of somatropin (Norditropin®) on final height in children with Noonan syndrome having being treated for up to 10 years with somatropin…
- Trial name
- NCT01529840
- Testing
- somatropin
- Where
- Sweden
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Locally Advanced Breast Cancer, Triple Negative Breast Cancer
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and…
- Conditions
- Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
- Trial name
- NCT06449222
- Testing
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 83 people
- Sponsor
- BioNTech SE
Breast Cancer
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
This observational study will characterize retrospectively patients with HER2-positive metastatic or locally advanced breast cancer who had received treatment with Herceptin (trastuzumab) in 1st line and who were without…
- Trial name
- NCT01480674
- Testing
- Trastuzumab
- Where
- 78 sites in France
- Volunteers
- 160 people
- Sponsor
- Hoffmann-La Roche
Advanced Breast Cancer
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
The main aim of this study was to evaluate the efficacy and safety of adding ribociclib to fulvestrant in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer.
- Trial name
- MONALEESA-3 (NCT02422615)
- Testing
- Ribociclib, Fulvestrant
- Where
- 174 sites in United States, Australia and 28 more
- Volunteers
- 726 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma
A Study of Tasisulam in Treating Participants With Malignant Melanoma
The primary purpose of this study is to determine the objective response rate (complete and partial response) for participants who receive tasisulam after one prior systemic treatment for unresectable or metastatic melanoma.
- Trial name
- NCT00383292
- Testing
- tasisulam
- Where
- 13 sites in United States, Australia
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Breast Neoplasms
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer
- Trial name
- NCT00373256
- Testing
- Sunitinib, paclitaxel, bevacizumab
- Where
- 250 sites in United States, Germany and 2 more
- Volunteers
- 488 people
- Sponsor
- Pfizer
HER2 + Breast Cancer
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
- Trial name
- NCT07294508
- Testing
- HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for…
- Trial name
- NEFERTT (NCT00915018)
- Testing
- Neratinib, Trastuzumab, Paclitaxel
- Where
- 195 sites in United States, Australia and 33 more
- Volunteers
- 479 people
- Sponsor
- Puma Biotechnology, Inc.
Malignant Melanoma
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults…
- Trial name
- NCT03820986
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 119 sites in United States, Australia and 16 more
- Volunteers
- 674 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic Breast Cancer
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer
- Trial name
- NCT05744687
- Testing
- SPH4336 Tablets 400mg
- Where
- 9 sites in China
- Volunteers
- 374 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Breast Cancer
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined.
- Trial name
- NCT00191854
- Testing
- gemcitabine, paclitaxel, carboplatin
- Where
- 18 sites in Brazil, China and 4 more
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Immune Thrombocytopenia (ITP)
A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP
The purpose of this study was to compare the ability of eltrombopag in combination with a short course of high-dose dexamethasone to induce sustained response off treatment in patients with newly-diagnosed ITP versus 1-3 cycles…
- Trial name
- XPAG-ITP (NCT04346654)
- Testing
- Eltrombopag, Dexamethasone
- Where
- 10 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals